Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 10;608(7923):609–617. doi: 10.1038/s41586-022-05066-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Authors 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 15 — a, Best percentage change from baseline tumour volume in patient-derived xenograft (PDX) models (n = 36) engrafted in female NOD-SCID (BL5001, BL5002) or BALB/c Nude (all other PDX models) mice and treated daily orally with vehicle or debio-1347 (n = 3 mice per PDX model and treatment group). Coloured bars indicate identified FGF/FGFR2 alterations detailed in Fig. 4c. b, c, Growth curves of indicated PDXs models engrafted in NOD-SCID or BALB/c Nude mice and treated daily orally with vehicle or debio-1347 (ES0204, Li0612, LI1035, BN2289, 60 mg/kg; GA1224, KI0551, 80 mg/kg; BL5001, day 1-14, 40 mg/kg; day 15-25, 60 mg/kg; n = 3 mice per PDX model and treatment group). d, Debio-1347 ΔT/ΔC response ratios in PDXs with FGF3/4/19 amp (n = 3) versus normal CN (n = 33). e, Debio-1347 ΔT/ΔC response ratios in PDXs with FGFR1 amp (n = 3), FGFR2 amp (n = 4), or FGFR3 amp (n = 1) versus normal CN (n = 28). f, Correlations of FGFR1, FGFR2, FGFR3, FGFR4, or composite FGFR expression versus debio-1347 ΔT/ΔC response ratios across PDXs. Composite FGFR expression was defined as high, if normalized expression > 3. g, Debio-1347 ΔT/ΔC response ratios in PDXs expressing E18-truncated FGFR2 (n = 6) or FGFR3 (n = 1) versus no truncation (n = 29). Data are represented as mean ± s.d. (a, b) or as median (centre line) ± IQR (25^th to 75^th percentile, box) and IQR ± 1.5 x IQR (whiskers) (d, f). P values were calculated with two-tailed unpaired Student’s t-tests (a), one-tailed two-way ANOVA and FDR multiple-testing corrections using the two-stage step-up method from Benjamini, Krieger, and Yekutieli (b, c), two-tailed Wilcoxon rank-sum tests (d, g), one-tailed one-way ANOVA and Tukey’s multiple-testing corrections (e), or two-tailed t-transformations of Pearson’s R correlation coefficients (f).

Source data